Related Experiment Video

Updated: Aug 7, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

New antiangiogenetic agents and non-small cell lung cancer

C Gridelli1, A Rossi, P Maione

  • 1Division of Medical Oncology, S.G. Moscati Hospital, Contrada Amoretta, Avellino, Italy. cgridelli@libero.it

Critical Reviews in Oncology/Hematology
|July 18, 2006
PubMed

Insights

Targeted therapies like bevacizumab combined with chemotherapy significantly improve survival in advanced non-squamous non-small cell lung cancer. This marks a new era for NSCLC treatment strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Angiogenesis, or new blood vessel formation, is crucial for tumor growth and metastasis.
  • Vascular Endothelial Growth Factor (VEGF) and its receptor are key targets in oncology, particularly for non-small cell lung cancer (NSCLC).
  • Targeted therapies, including monoclonal antibodies and tyrosine kinase inhibitors (TKIs), are being developed to inhibit VEGF signaling.

Purpose of the Study:

  • To review the role of VEGF-targeted therapies in non-small cell lung cancer treatment.
  • To highlight the efficacy of bevacizumab and VEGFR-TKIs in preclinical and clinical settings.
  • To discuss the potential of combination therapies for improved NSCLC outcomes.

Main Methods:

  • Review of a randomized phase III trial for bevacizumab plus chemotherapy in advanced non-squamous NSCLC.
  • Examination of preclinical and early clinical data for VEGFR-2 inhibitor ZD6474.
  • Analysis of a phase I/II study combining EGFR-TKI erlotinib with bevacizumab in NSCLC patients.

Main Results:

  • The combination of bevacizumab and chemotherapy demonstrated a statistically significant survival advantage over chemotherapy alone in advanced non-squamous NSCLC.
  • Bevacizumab represents the first targeted therapy to show superior efficacy when combined with chemotherapy in NSCLC.
  • Early data suggest promising antitumor activity for ZD6474 and the combination of erlotinib with bevacizumab.

Conclusions:

  • Targeted therapies, particularly anti-VEGF agents, combined with chemotherapy, represent a significant advancement in NSCLC treatment.
  • Bevacizumab plus chemotherapy offers a new standard of care for advanced non-squamous NSCLC.
  • Combination strategies involving multiple targeted agents may define the next generation of NSCLC therapy.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...